Abstract
The effects of chitosan-oligosaccharide (GO2KA1) on postprandial blood glucose levels in adults with normal blood glucose levels were investigated. Postprandial blood glucose levels were measured at 30, 60, 90, and 120 min after sucrose administration with and without 500 mg of GO2KA1. GO2KA1 administration reduced the area under the blood glucose-time curve (AUC) and the blood glucose peak (C max ) values while the time of peak plasma concentration of blood glucose (T max ) value was significantly (p<0.05) increased, compared to controls. GO2KA1 reduced postprandial blood glucose level increases via slower absorption of glucose in the small intestine based on carbohydrate hydrolyzing enzyme inhibition.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Refrerences
Centers for Disease Control and Prevention. National diabetes prevention. Available from: http://www.cdc.gov/diabetes/prevention/prediabetes.html. Accessed Sep. 15, 2013.
World Health Organization. Diabetes. Available from: http://who.int/mediacentre/factsheets/fs312/en/index.html. Accessed Apr. 20, 2013.
American Diabetes Association. Diagnosing diabetes and learning about prediabetes. Available from: http://www.diabetes.org/diabetesbasics/diagnosis/?loc=DropDownDB-diagnosis. Accessed Apr. 2013.
Maeda Y, Kimura Y. Antitumor effects of various low-molecularweight chitosans are due to increased natural killer activity of intestinal intraepithelial lymphocytes in sarcoma 180-bearing mice. J. Nutr. 134: 945–950 (2004)
Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am. J. Physiol- Endoc. M. 284: E671–E678 (2003)
Ko GT, Cockram CS, Chan JC. How to minimize missing those subjects with high 2HR plasma glucose but ‘normaľ fasting plasma glucose levels? J. Med. 32: 53–65 (2001)
Holman RR. Assessing the potential for α-glucosidase inhibitors in prediabetic states. Diabetes Res. Clin. Pract. 40 (Suppl. 1): S21–S25 (1998)
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA1c. Diabetes Care 26: 881–885 (2003)
Xia W, Liu P, Zhang J, Chen J. Biological activities of chitosan and chitooligosaccharides. Food Hydrocolloid. 25: 170–179 (2011)
Qin C, Du Y, Xiao L, Li Z, Gao X. Enzymic preparation of watersoluble chitosan and their antitumor activity. Int. J. Biol. Macromole. 31: 111–117 (2002)
Kim SK, Rajapakse N. Enzymatic production and biological activities of chitosan oligosaccharides (COS): A review. Carbohyd. Polym. 62: 357–368 (2005)
Kumar SG, Rahman MA, Lee SH, Hwang HS, Kim HA, Yun JW. Plasma proteome analysis for anti-obesity and anti-diabetic potentials of chitosan oligosaccharides in ob/ob mice. Proteomics 9: 2149–2162 (2009)
Kondo Y, Nakatani A, Hayashi K, Ito M. Low molecular weight chitosan prevents the progression of low dose streptozotocininduced slowly progressive diabetes mellitus in mice. Biol. Pharmaceut. Bull. 23: 1458–1464 (2000)
Jo SH, Ha KS, Moon KS, Kim JG, Oh CG, Kim YC, Apostolidis E, Kwon YI. Molecular weight dependent glucose lowering effect of low molecular weight chitosan oligosaccharide (GO2KA1) on postprandial blood glucose level in SD rats model. Int. J. Mol. Sci. 14: 14214–14224 (2013)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jo, SH., Ha, KS., Lee, JW. et al. The reduction effect of low molecular weight chitosan oligosaccharide (GO2KA1) on postprandial blood glucose levels in healthy individuals. Food Sci Biotechnol 23, 971–973 (2014). https://doi.org/10.1007/s10068-014-0131-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10068-014-0131-3